Massachusetts Financial Services’s Viking Therapeutics VKTX Stock Holding History

Massachusetts Financial Services’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,357,241	Closed	-$54.6M	–	924
2024 Q4	$54.6M	Buy	1,357,241 +1,108,972	+447%	+$63.2M	0.02%	455
2024 Q3	$15.7M	Buy	248,269 +11,668	+5%	+$685K	﹤0.01%	617
2024 Q2	$12.5M	Sell	236,601 -56,984	-19%	-$3.74M	﹤0.01%	623
2024 Q1	$24.1M	Sell	293,585 -369,570	-56%	-$16.4M	0.01%	557
2023 Q4	$12.3M	Buy	+663,155	New	+$8.67M	﹤0.01%	610

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Massachusetts Financial Services's VKTX Position: Q1 2025 in Review

Massachusetts Financial Services sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 1,357,241 shares — an estimated $54.6M sold.

Massachusetts Financial Services first reported a position in VKTX in Q4 2023 and held it in 5 quarters. The position peaked at $54.6M in Q4 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Massachusetts Financial Services reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Massachusetts Financial Services sold 1,357,241 Viking Therapeutics shares in Q1 2025, an estimated $54.6M.
Massachusetts Financial Services first reported a position in Viking Therapeutics in Q4 2023 and held it in 5 quarters.
Massachusetts Financial Services's Viking Therapeutics position peaked at $54.6M in Q4 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Massachusetts Financial Services's 13F filing for Q1 2025, filed 2 May 2025.